Can palliative radiotherapy influence prostate-specific antigen response in patients with castrate-resistant prostate cancer treated with systemic therapy (chemotherapy or abiraterone)?-a report of three cases

被引：3
作者：
Hingorani, Mohan [1 ]
Dixit, Sanjay [1 ]
Pugazhenthi, Pattu [1 ]
Hawkyard, Simon [2 ]
Robertson, Andrew [2 ]
Khafagy, Richard [2 ]
机构：
[1] NHS Trust, Castle Hill Hosp, Dept Clin Oncol, Cottingham HU16 5JQ, East Riding Yor, England
[2] Scarborough Dist Gen Hosp, Dept Urol, Scarborough M1P 2V5, ON, Canada
来源：
CANCER BIOLOGY & MEDICINE | 2015年 / 12卷 / 01期
关键词：
Chemotherapy; Palliative; Prostate cancer; Radiotherapy;
D O I：
10.7497/j.issn.2095-3941.2014.0025
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Palliative radiotherapy (pRT) is primarily employed for palliation of bone pain in patients with castrate-resistant prostate cancer (CRPC). However, evidence that pRT influences prostate-specific antigen response in patients with CRPC on systemic therapy is lacking. We describe three cases of CRPC progressing after treatment with docetaxel (n=2) and abiraterone (n=1), who responded unusually after pRT for bone pain with the development of a significant biochemical response and restoration of response to systemic therapy. The possibility of pRT influencing metastatic disease in CRPC has not been previously reported, and raises the possibility of radiation-induced modulation of anti-tumor immune response mechanisms that may play a role in the restoration of response to systemic treatment.
引用
收藏
页码：60 / 63
页数：4
相关论文
共 50 条
  • [31] Prostate-specific antigen nadir within 1 year of radiotherapy combined with hormone therapy predicts cancer-specific mortality and biochemical recurrence-free survival in prostate cancer patients
    Cetin, Ilknur Alsan
    Akay, Sitki Utku
    Sengoz, Meric
    BMC UROLOGY, 2022, 22 (01)
  • [32] Three-month Prostate-specific Antigen Level After Androgen Deprivation Therapy Predicts Survival in Patients With Metastatic Castration-sensitive Prostate Cancer
    Fujimoto, Naohiro
    Shiota, Masaki
    Matsukawa, Takuo
    Minato, Akinori
    Tomisaki, Ikko
    Ohnishi, Rei
    Eto, Masatoshi
    IN VIVO, 2021, 35 (02): : 1101 - 1108
  • [33] Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapy
    Stangl-Kremser, Judith
    Sun, Michael
    Ho, Benedict
    Thomas, Joseph
    Nauseef, Jones. T. T.
    Osborne, Joseph. R. R.
    Molina, Ana
    Sternberg, Cora. N. N.
    Nanus, David. M. M.
    Bander, Neil. H. H.
    Tagawa, Scott
    PROSTATE, 2023, 83 (14) : 1351 - 1357
  • [34] Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [177Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate Cancer
    Stangl-Kremser, Judith
    Rasul, Sazan
    Salami, Simpa S.
    Zaslavsky, Alexander
    Udager, Aaron
    Mazal, Peter
    Kain, Renate
    Comperat, Eva
    Hacker, Marcus
    Haug, Alexander
    Mitterhauser, Markus
    Pozo-Salido, Carmen
    Steinbach, Christina
    Hassler, Melanie R.
    Kramer, Gero
    Shariat, Shahrokh F.
    Palapattu, Ganesh S.
    EUROPEAN UROLOGY OPEN SCIENCE, 2021, 30 : 63 - 66
  • [35] Visceral Metastases as Predictors of Response and Survival Outcomes in Patients of Castration-Resistant Prostate Cancer Treated With 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy A Systematic Review and Meta-analysis
    Satapathy, Swayamjeet
    Mittal, Bhagwant Rai
    Sood, Ashwani
    CLINICAL NUCLEAR MEDICINE, 2020, 45 (12) : 935 - 942
  • [36] Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration- resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study
    Flippot, Ronan
    Telli, Tugce
    Velev, Maud
    Flechon, Aude
    De Vries-Brilland, Manon
    Turpin, Leoa
    Bergman, Andries
    Turco, Fabio
    Mahammedi, Hakim
    Fendler, Wolfgang P.
    Giraudet, Anne-Laure
    Josset, Quentin
    Montravers, Francoise
    Vogel, Wouter
    Gillessen, Silke
    Vilei, Simona Berardi
    Herrmann, Ken
    Kryza, David
    Paone, Gaetano
    Hadaschik, Boris
    Merlin, Charles
    Dufour, Pierre-Alban
    Bernard-Tessier, Alice
    Naoun, Natacha
    Patrikidou, Anna
    Garcia, Camilo
    Foulon, Stephanie
    Pages, Arnaud
    Fizazi, Karim
    EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (05): : 1132 - 1140
  • [37] Prostate-specific antigen response after short-term hormone therapy plus external-beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413
    Cury, Fabio L.
    Hunt, Daniel
    Roach, Mack, III
    Shipley, William
    Gore, Elizabeth
    Hsu, I-Chow
    Krisch, Robert E.
    Seider, Michael J.
    Sandler, Howard
    Lawton, Colleen
    CANCER, 2013, 119 (11) : 1999 - 2004
  • [38] Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy
    Sue Ping Thang
    Violet, John
    Sandhu, Shahneen
    Iravani, Amir
    Akhurst, Tim
    Kong, Grace
    Kumar, Aravind Ravi
    Murphy, Declan G.
    Williams, Scott G.
    Hicks, Rodney J.
    Hofman, Michael S.
    EUROPEAN UROLOGY ONCOLOGY, 2019, 2 (06): : 670 - 676
  • [39] Exponential Rise in Prostate-Specific Antigen (PSA) during Anti-Androgen Withdrawal Predicts PSA Flare after Docetaxel Chemotherapy in Patients with Castration-Resistant Prostate Cancer
    Han, Kyung Seok
    Hong, Sung Joon
    YONSEI MEDICAL JOURNAL, 2015, 56 (02) : 368 - 374
  • [40] Three years' clinical practice of Radium-223 therapy in patients with symptomatic bone metastases from metastatic castrate-resistant prostate cancer: a single-centre experience
    Gazzilli, Maria
    Durmo, Rexhep
    Cossalter, Erika
    Cerudelli, Elisabetta
    Panarotto, Maria Beatrice
    Albano, Domenico
    Bertagna, Francesco
    Giubbini, Raffaele
    NUCLEAR MEDICINE COMMUNICATIONS, 2020, 41 (04) : 300 - 307
12345